Weill Cornell Researchers Discover T Cells Secrete DNA-Laden Vesicles to Eliminate Cancerous Immune Blind Spots

Weill Cornell study finds T cells release DNA-carrying vesicles that restore tumor visibility, offering a new strategy for treating immunologically silent cancers.

By: AXL Media

Published: May 1, 2026, 11:05 AM EDT

Source: Information for this report was sourced from EurekAlert!

Uncovering a Natural Mechanism for Immune Amplification

The scientific understanding of how the body orchestrates its defense against malignancy has expanded with the discovery of a novel T cell communication pathway. Investigators at Weill Cornell Medicine have found that activated T cells secrete extracellular vesicles—nanoscale capsules—that carry specific genetic payloads to other cells. Unlike previous observations of tumor-secreted vesicles that often suppress immunity, these T cell-derived particles act as potent stimulants. By transferring snippets of DNA into both immune and malignant cells, these vesicles enhance the body’s ability to detect and destroy threats that would otherwise remain hidden.

The Discovery of Surface-Bound Genetic Payloads

Initial experiments conducted by the laboratory of Dr. David Lyden revealed that these T cell vesicles do not carry random genetic material. Instead, they are enriched with DNA fragments related to immune-related genes, particularly those involved in displaying antigens. Dr. Haiying Zhang noted that these fragments are surprisingly abundant on the surface of the vesicles rather than just tucked inside. This strategic placement, combined with a specialized surface enzyme that acts as a "molecular drill," allows the vesicles to transfer their DNA directly into the nucleus of a recipient cell for transient expression.

Restoring Visibility to Immunologically Silent Tumors

One of the primary challenges in oncology is the existence of "silent" tumors—cancers that suppress their own antigen-presenting processes to become invisible to T cells. The study, published in Cancer Cell, demonstrated that infusing these DNA-carrying vesicles can reverse this invisibility. In preclinical models, the vesicles were taken up by tumor cells, effectively "re-arming" them with the machinery needed to be recognized by the immune system. This process results in tumors being better infiltrated by T cells, leading to significantly slower growth rates in aggressive cancers such as glioblastoma and pancreatic cancer.